Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline
Publication
, Conference
Kronn, D; Davison, J; Brassier, A; Broomfield, A; Hahn, SH; Kumada, S; Labarthe, F; Ohki, H; Prakalapakorn, SG; Haack, KA; Meng, X; Sparks, S ...
Published in: Molecular Genetics and Metabolism
February 2022
Duke Scholars
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2022
Volume
135
Issue
2
Start / End Page
S68 / S68
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kronn, D., Davison, J., Brassier, A., Broomfield, A., Hahn, S. H., Kumada, S., … Kishnani, P. S. (2022). Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. In Molecular Genetics and Metabolism (Vol. 135, pp. S68–S68). Elsevier BV. https://doi.org/10.1016/j.ymgme.2021.11.171
Kronn, David, James Davison, Anaïs Brassier, Alexander Broomfield, Si Houn Hahn, Satoko Kumada, François Labarthe, et al. “Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline.” In Molecular Genetics and Metabolism, 135:S68–S68. Elsevier BV, 2022. https://doi.org/10.1016/j.ymgme.2021.11.171.
Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, et al. Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. In: Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S68–S68.
Kronn, David, et al. “Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline.” Molecular Genetics and Metabolism, vol. 135, no. 2, Elsevier BV, 2022, pp. S68–S68. Crossref, doi:10.1016/j.ymgme.2021.11.171.
Kronn D, Davison J, Brassier A, Broomfield A, Hahn SH, Kumada S, Labarthe F, Ohki H, Prakalapakorn SG, Haack KA, Meng X, Sparks S, Tammireddy S, Wilson C, Zaher A, Zhou T, Chien Y-H, Kishnani PS. Mini-COMET study: Safety, biomarker, and efficacy data after avalglucosidase alfa dosing for ≥ 97 weeks in participants with infantile-onset pompe disease (IOPD) previously treated with alglucosidase alfa who had demonstrated clinical decline. Molecular Genetics and Metabolism. Elsevier BV; 2022. p. S68–S68.
Published In
Molecular Genetics and Metabolism
DOI
ISSN
1096-7192
Publication Date
February 2022
Volume
135
Issue
2
Start / End Page
S68 / S68
Publisher
Elsevier BV
Related Subject Headings
- Genetics & Heredity
- 3202 Clinical sciences
- 3105 Genetics
- 1103 Clinical Sciences